Oruka Therapeutics, Inc.
ORKA- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0000907654
In the last 90 days, Oruka Therapeutics, Inc. insiders filed 0 open-market purchases and 16 sales; 255 institutions reported holding it in 13F filings for Q2 2026, worth $7.05B in total; Viking Global Investors is the only superinvestor holding it.
13F holders, Q3 2021
Institutional positions in Oruka Therapeutics, Inc. as of Sep 30, 2021. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 19
- +2 vs. Q2 2021
- Shares held
- 1.53M
- +335.0K (+28.1%) vs. Q2 2021
- Total value
- $4.53M
- +$361.0K (+8.7%) vs. Q2 2021
- New holders
- 6
- 7 more added
- Sold out
- 4
- 4 more reduced
Compare with Q2 2021: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting ORKA on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 255 | $7.05B |
| Q1 2026 | 184 | $2.55B |
| Q4 2025 | 143 | $1.60B |
| Q3 2025 | 105 | $875.8M |
| Q2 2025 | 81 | $386.0M |
| Q1 2025 | 71 | $326.1M |
| Q4 2024 | 66 | $606.6M |
| Q3 2024 | 42 | $604.2M |
| Q2 2024 | 32 | $49.4M |
| Q1 2024 | 23 | $12.7M |
| Q4 2023 | 25 | $12.7M |
| Q3 2023 | 21 | $6.55M |
| Q2 2023 | 23 | $5.75M |
| Q1 2023 | 26 | $5.02M |
| Q4 2022 | 22 | $6.19M |
| Q3 2022 | 25 | $4.58M |
| Q2 2022 | 24 | $4.17M |
| Q1 2022 | 22 | $2.60M |
| Q4 2021 | 21 | $2.41M |
| Q3 2021 | 19 | $4.53M |
| Q2 2021 | 17 | $4.16M |
| Q1 2021 | 17 | $3.20M |
Institutions, Q3 2021
Shares, value and share of portfolio for each institution holding Oruka Therapeutics, Inc.; share changes are against Q2 2021.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Bank of America Corp | 105 | $0 | 0.00% | +74+238.7% | Added |
| Wells Fargo & Company | 88 | $0 | 0.00% | −66−42.9% | Reduced |
| Advisor Group Holdings, Inc. | 107 | $0 | 0.00% | −50−31.8% | Reduced |
| Morgan Stanley | 17 | $0 | 0.00% | +17 | New |
| Parallel Advisors, LLC | 244 | $1.00K | 0.00% | +244 | New |
| Simplex Trading, LLC | 1,270 | $4.00K | 0.00% | +1,270 | New |
| Tower Research Capital LLC (TRC) | 2,341 | $7.00K | 0.00% | +2,272+3,292.8% | Added |
| Minerva Advisors LLC | 10,000 | $30.0K | 0.02% | +10,000 | New |
| Millennium Management LLC | 15,874 | $47.0K | 0.00% | +15,874 | New |
| Alpine Global Management, LLC | 16,715 | $49.0K | 0.01% | +16,715 | New |
| Northern Trust Corp | 17,517 | $52.0K | 0.00% | 00.0% | Unchanged |
| Citadel Advisors LLC | 29,007 | $86.0K | 0.00% | −23,179−44.4% | Reduced |
| Tekla Capital Management LLC | 32,461 | $96.0K | 0.00% | 00.0% | Unchanged |
| State Street Corp | 69,937 | $207.0K | 0.00% | +900+1.3% | Added |
| Geode Capital Management, LLC | 95,358 | $282.0K | 0.00% | +7,699+8.8% | Added |
| Susquehanna International Group, LLP | 110,035 | $326.0K | 0.00% | +8,288+8.1% | Added |
| BlackRock Inc. | 268,394 | $795.0K | 0.00% | −5,048−1.8% | Reduced |
| Vanguard Group Inc | 417,258 | $1.24M | 0.00% | +18,751+4.7% | Added |
| Gsa Capital Partners LLP | 441,945 | $1.31M | 0.13% | +311,550+238.9% | Added |
| Goldman Sachs Group Inc | 0 | $0 | 0.00% | −13,918−100.0% | Sold out |
| XTX Topco Ltd | 0 | $0 | 0.00% | −10,846−100.0% | Sold out |
| UBS Group AG | 0 | $0 | 0.00% | −5,365−100.0% | Sold out |
| JPMorgan Chase & Co | 0 | $0 | 0.00% | −133−100.0% | Sold out |